In subset analysis, the positive predictive value of MSA for recurrent disease is much higher in patient groups with an FGFR3 wild-type from resected tumor samples, as it reaches 100% at 24 months of follow-up [96,97,98]. This evidence concerns the gene FGFR3 and neoplasm.